AHA Coding Clinic® for HCPCS - 2005 Quarter 3; FOR your INFORMATION
Newly-approved drugs and biologicals eligible for pass-through status
As you will note in Fig. 5, the following drugs and biologicals were designated as eligible for pass-through status under the OPPS effective July 1, 2005. Fig. 5 HCPCS APC SI Long descriptor C9127 9127 G Injection, Paclitaxel Protein Bound Particles, per 1 mg C9128 9128 G Injection, Pegaptiamib Sodium, per 0.3 mg C9129 9129 G Injection, Clofarabine, per 1 mg J8501 * 0868 G Aprepitant, oral, 5 mg * J8501 was approved for pass-through status effective April 6, 2005 ...
Subscribe or sign in to view the full article.
Article Overview
This short Find-A-Code article covers newly approved drugs and biologicals that were designated as eligible for pass-through status under the OPPS, with an effective date noted in the source. It is aimed at coding and billing professionals who need to track outpatient payment updates and the identifiers associated with the listed products. The article presents a compact figure with the relevant code-set references and a brief note about one item’s approval timing.
Why This Topic Matters
Pass-through status updates can affect outpatient billing, payment processing, and charge capture workflows. Readers use this kind of article to stay current on payer-relevant drug and biological status changes tied to OPPS guidance.
What You Will Learn
- Which outpatient drug and biological updates are highlighted in the source
- How the article frames pass-through status within OPPS
- Which billing identifiers are referenced alongside the newly approved products
- What effective-date context is provided in the source
Who Should Read This
- Medical coders
- Outpatient hospital billing staff
- Revenue cycle professionals
- Compliance teams
- Charge capture specialists
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com